Company intelligence / Profile preview

SeniorLife.AI

Seattle, Washington, United Statesseniorlife.ai ↗

Ownership: Private
Development stage: Commercial

Overview

SeniorLife.AI offers an FDA-approved, clinically validated software platform that uses vision-based artificial intelligence to assess mobility and cognitive health risks in older adults. The solution is proven to reduce fall rates, improve rehabilitation outcomes, lower hospital readmissions, and support early detection of cognitive decline. Clinical results show significant improvements in balance metrics and a reduction in major injury incidents among users[1][4].

Therapeutic areas: Neurology
Modalities: DeviceNon-pharmacological therapy (AI-based digital assessment tool)
Industry: Digital Health Medical Devices

Partnerships

Concierge Care Advisors[4]

Beyond the preview

Go deeper on SeniorLife.AI.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SeniorLife.AI.

Explore the full profile